These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeted therapy using alpha emitters. Vaidyanathan G, Zalutsky MR. Phys Med Biol; 1996 Oct; 41(10):1915-31. PubMed ID: 8912371 [Abstract] [Full Text] [Related]
3. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Cancer Res; 1994 Sep 01; 54(17):4719-25. PubMed ID: 8062270 [Abstract] [Full Text] [Related]
4. Radioimmunotherapy with alpha-particle emitting radionuclides. Zalutsky MR, Pozzi OR. Q J Nucl Med Mol Imaging; 2004 Dec 01; 48(4):289-96. PubMed ID: 15640792 [Abstract] [Full Text] [Related]
5. Advancements in cancer therapy with alpha-emitters: a review. Imam SK. Int J Radiat Oncol Biol Phys; 2001 Sep 01; 51(1):271-8. PubMed ID: 11516878 [Abstract] [Full Text] [Related]
6. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons. Aghevlian S, Boyle AJ, Reilly RM. Adv Drug Deliv Rev; 2017 Jan 15; 109():102-118. PubMed ID: 26705852 [Abstract] [Full Text] [Related]
7. Radioimmunotherapy with α-particle-emitting radionuclides. Seidl C. Immunotherapy; 2014 Jan 15; 6(4):431-58. PubMed ID: 24815783 [Abstract] [Full Text] [Related]
8. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Vaidyanathan G, Zalutsky MR. Curr Radiopharm; 2011 Oct 15; 4(4):283-94. PubMed ID: 22202151 [Abstract] [Full Text] [Related]
9. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. Lucignani G. Eur J Nucl Med Mol Imaging; 2008 Sep 15; 35(9):1729-33. PubMed ID: 18542953 [No Abstract] [Full Text] [Related]
10. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Zalutsky MR, Schuster JM, Garg PK, Archer GE, Dewhirst MW, Bigner DD. Recent Results Cancer Res; 1996 Sep 15; 141():101-22. PubMed ID: 8722422 [No Abstract] [Full Text] [Related]
11. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals. Ma D, McDevitt MR, Finn RD, Scheinberg DA. Appl Radiat Isot; 2001 Oct 15; 55(4):463-70. PubMed ID: 11545498 [Abstract] [Full Text] [Related]
12. Astatine-211: production and availability. Zalutsky MR, Pruszynski M. Curr Radiopharm; 2011 Jul 15; 4(3):177-85. PubMed ID: 22201707 [Abstract] [Full Text] [Related]
14. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Andersson H, Palm S, Lindegren S, Bäck T, Jacobsson L, Leser G, Horvath G. Anticancer Res; 2001 Sep 15; 21(1A):409-12. PubMed ID: 11299770 [Abstract] [Full Text] [Related]
15. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Allen BJ. Australas Radiol; 1999 Nov 15; 43(4):480-6. PubMed ID: 10901964 [Abstract] [Full Text] [Related]
16. Tumor therapy with targeted atomic nanogenerators. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Science; 2001 Nov 16; 294(5546):1537-40. PubMed ID: 11711678 [Abstract] [Full Text] [Related]